Study:
A Phase II Trial of Patients With Limited Stage Small Cell Lung Cancer Treated With Thoracic Radiation Therapy and Chemotherapy With Cisplatin/Etoposide Followed by Cisplatin/Etoposide and Anti-Idiotype Monoclonal Antibody Vaccines
Rationale:
Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor
cells. Vaccines may make the body build an immune response to kill tumor cells. Combining
chemotherapy and radiation therapy with vaccine therapy may kill more tumor cells.
Purpose:
Phase II trial to study the effectiveness of combining chemotherapy and radiation
therapy with vaccine therapy in treating patients who have limited-stage small cell lung
cancer.
Study Status: Terminated
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Lung Cancer |
Biological: monoclonal antibody 11D10 anti-idiotype vaccine
Biological: monoclonal antibody GD2 anti-idiotype vaccine
Drug: cisplatin
Drug: etoposide
Radiation: radiation therapy |
Phase 2 |
Verified by
Southwest Oncology Group
June, 2012
Sponsored by: Southwest Oncology Group
Information provided by: Southwest Oncology Group
ClinicalTrials.gov identifier: NCT00045617
Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195-9001
United States
Abdul-Rahman Jazieh, MD, MPH., Study Chair